乐可以重新用于治疗内脏莱什曼病吗?
Juliana Martins Ribeiro1,2, Eliane de Morais Teixeira3, Líndicy Leidicy Alves3
1Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Antimicrobial agents and chemotherapy
|October 10, 2024
概括
芳香酶抑制剂莱特 (LET) 在治疗内脏莱什曼病方面表现有前途. 这项研究发现,在体外和体外模型中,LET有效降低了Leishmania infantum寄生虫负荷,并调节了免疫反应.
科学领域:
- 寄生虫学的寄生虫学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由Leishmania infantum引起的内脏莱什曼病 (VL) 是一种严重的,可能致命的疾病.
- 目前缺乏预防措施,VL的治疗选择有限.
- 莱特醇 (LET) 是一种用于乳腺癌的芳香酶抑制剂,研究了其抗莱什曼的活性.
研究的目的:
- 评估莱斯曼尼菌对莱斯曼尼菌婴儿的抗莱斯曼尼菌活性.
- 评估在L.婴儿感染的背景下LET的免疫调节潜力.
- 探索LET重新定位用于治疗内脏莱什曼病的可能性.
主要方法:
- 在体外研究中,使用人类THP-1细胞衍生巨细胞感染L. infantum.
- 用LET治疗的人类外周血液白细胞的活体分析.
- 在体内研究使用小鼠模型的L.婴儿感染.
主要成果:
- 在实验室中,LET对L. infantum前性和前性阶段表现出活性.
- LET减少了单细胞和中性粒细胞的寄生虫内化,并调节了细胞因子的产生 (增加IL-12/TNF-α,减少IL-10/TGF-β).
- 在体内,LET显著降低了肝脏和里的寄生虫负荷,增加了TNF-α/IFN-γ的产生,并促进了颗粒瘤的成熟.
结论:
- 莱特醇表现出显著的抗莱什曼病毒活性和对婴儿莱什曼病毒的免疫调节作用.
- 在实验模型中,LET有效降低了寄生虫负担,并增强了抗寄生虫免疫反应.
- 重定位莱特醇可能为人类内脏莱什曼病提供了一个有前途的治疗策略.
关键词:
莱什曼尼亚婴儿病 (英语:Leishmania infantum) 是一种疾病.化疗 化疗是一种化学疗法.药物重新定位 药物重新定位人类内脏莱什曼病免疫调节 免疫调节 免疫调节莱特罗斯 (Letrozole) 是一种可靠的药物.更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.0K
06:57In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
8.2K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...